ALP Bio AG raised €1.9M in a pre-seed round announced on April 30, 2026. to accelerate their platform which combines human immune organoid biology with generative AI to help antibody developers identify, understand, and reduce immunogenicity risk earlier in drug development.
to accelerate their platform which combines human immune organoid biology with generative AI to help antibody developers identify, understand, and reduce immunogenicity risk earlier in drug development.
ALP Bio AG, based in Schlieren, Switzerland, announced €1.9M in pre-seed financing on April 30, 2026.
Participants include Venture Kick, 42Cap.
A biotechnology company developing small molecule drugs that target RNA modifying enzymes for the treatment of cancer.
Hypervision Surgical develops computer-assisted tissue analysis tools for surgeons.
mbiomics develops microbiome analysis technology to inform targeted therapies.